Eli Lilly Acquires Centessa Pharmaceuticals for Orexin Receptor Research

Eli Lilly (LLY) has acquired Centessa Pharmaceuticals to advance the development of orexin receptor 2 agonists, a new class of drugs targeting sleep-wake disorders. The acquisition aims to address unmet needs in neuroscience and expand Eli Lilly's portfolio into brain health solutions.

By Maham Fatima Fri, June 26, 2026 at 11:06 AM GMT+3 1 min read · Yahoo Finance · June 26, 2026, 08:06 UTC

Eli Lilly Acquires Centessa Pharmaceuticals for Orexin Receptor Research

Tickers: $LLY

Topics: neuroscience pharmaceuticals sleep disorders

Read the full article at Yahoo Finance

More World news

Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC